212 related articles for article (PubMed ID: 29246309)
1. Fine and Predictable Tuning of TALEN Gene Editing Targeting for Improved T Cell Adoptive Immunotherapy.
Gautron AS; Juillerat A; Guyot V; Filhol JM; Dessez E; Duclert A; Duchateau P; Poirot L
Mol Ther Nucleic Acids; 2017 Dec; 9():312-321. PubMed ID: 29246309
[TBL] [Abstract][Full Text] [Related]
2. Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies.
Poirot L; Philip B; Schiffer-Mannioui C; Le Clerre D; Chion-Sotinel I; Derniame S; Potrel P; Bas C; Lemaire L; Galetto R; Lebuhotel C; Eyquem J; Cheung GW; Duclert A; Gouble A; Arnould S; Peggs K; Pule M; Scharenberg AM; Smith J
Cancer Res; 2015 Sep; 75(18):3853-64. PubMed ID: 26183927
[TBL] [Abstract][Full Text] [Related]
3. Optimized tuning of TALEN specificity using non-conventional RVDs.
Juillerat A; Pessereau C; Dubois G; Guyot V; Maréchal A; Valton J; Daboussi F; Poirot L; Duclert A; Duchateau P
Sci Rep; 2015 Jan; 5():8150. PubMed ID: 25632877
[TBL] [Abstract][Full Text] [Related]
4. Automated generation of gene-edited CAR T cells at clinical scale.
Alzubi J; Lock D; Rhiel M; Schmitz S; Wild S; Mussolino C; Hildenbeutel M; Brandes C; Rositzka J; Lennartz S; Haas SA; Chmielewski KO; Schaser T; Kaiser A; Cathomen T; Cornu TI
Mol Ther Methods Clin Dev; 2021 Mar; 20():379-388. PubMed ID: 33575430
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
[TBL] [Abstract][Full Text] [Related]
6. Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing.
Jo S; Das S; Williams A; Chretien AS; Pagliardini T; Le Roy A; Fernandez JP; Le Clerre D; Jahangiri B; Chion-Sotinel I; Rozlan S; Dessez E; Gouble A; Dusséaux M; Galetto R; Duclert A; Marcenaro E; Devillier R; Olive D; Duchateau P; Poirot L; Valton J
Nat Commun; 2022 Jun; 13(1):3453. PubMed ID: 35773273
[TBL] [Abstract][Full Text] [Related]
7. Optimized two-step electroporation process to achieve efficient nonviral-mediated gene insertion into primary T cells.
Yang M; Tkach D; Boyne A; Kazancioglu S; Duclert A; Poirot L; Duchateau P; Juillerat A
FEBS Open Bio; 2022 Jan; 12(1):38-50. PubMed ID: 34510816
[TBL] [Abstract][Full Text] [Related]
8. Non-viral expression of chimeric antigen receptors with multiplex gene editing in primary T cells.
Cappabianca D; Li J; Zheng Y; Tran C; Kasparek K; Mendez P; Thu R; Maures T; Capitini CM; Deans R; Saha K
Front Bioeng Biotechnol; 2024; 12():1379900. PubMed ID: 38882639
[TBL] [Abstract][Full Text] [Related]
9. CRISPR/Cas9 genome editing: Fueling the revolution in cancer immunotherapy.
Liu X; Zhao Y
Curr Res Transl Med; 2018 May; 66(2):39-42. PubMed ID: 29691200
[TBL] [Abstract][Full Text] [Related]
10. Detection of chromosomal alteration after infusion of gene-edited allogeneic CAR T cells.
Sasu BJ; Opiteck GJ; Gopalakrishnan S; Kaimal V; Furmanak T; Huang D; Goswami A; He Y; Chen J; Nguyen A; Balakumaran A; Shah NN; Hamadani M; Bone KM; Prashad S; Bowen MA; Pertel T; Embree HD; Gidwani SG; Chang D; Moore A; Leonard M; Amado RG
Mol Ther; 2023 Mar; 31(3):676-685. PubMed ID: 36518079
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological interventions enhance virus-free generation of
Kath J; Du W; Pruene A; Braun T; Thommandru B; Turk R; Sturgeon ML; Kurgan GL; Amini L; Stein M; Zittel T; Martini S; Ostendorf L; Wilhelm A; Akyüz L; Rehm A; Höpken UE; Pruß A; Künkele A; Jacobi AM; Volk HD; Schmueck-Henneresse M; Stripecke R; Reinke P; Wagner DL
Mol Ther Methods Clin Dev; 2022 Jun; 25():311-330. PubMed ID: 35573047
[TBL] [Abstract][Full Text] [Related]
12. Universal CARs, universal T cells, and universal CAR T cells.
Zhao J; Lin Q; Song Y; Liu D
J Hematol Oncol; 2018 Nov; 11(1):132. PubMed ID: 30482221
[TBL] [Abstract][Full Text] [Related]
13. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection.
Eyquem J; Mansilla-Soto J; Giavridis T; van der Stegen SJ; Hamieh M; Cunanan KM; Odak A; Gönen M; Sadelain M
Nature; 2017 Mar; 543(7643):113-117. PubMed ID: 28225754
[TBL] [Abstract][Full Text] [Related]
14. Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells.
Hu B; Zou Y; Zhang L; Tang J; Niedermann G; Firat E; Huang X; Zhu X
Hum Gene Ther; 2019 Apr; 30(4):446-458. PubMed ID: 29706119
[TBL] [Abstract][Full Text] [Related]
15. Comparison of gene editing efficiencies of CRISPR/Cas9 and TALEN for generation of MSTN knock-out cashmere goats.
Zhang J; Liu J; Yang W; Cui M; Dai B; Dong Y; Yang J; Zhang X; Liu D; Liang H; Cang M
Theriogenology; 2019 Jul; 132():1-11. PubMed ID: 30981084
[TBL] [Abstract][Full Text] [Related]
16. Gene Augmentation and Editing to Improve TCR Engineered T Cell Therapy against Solid Tumors.
Lo Presti V; Buitenwerf F; van Til NP; Nierkens S
Vaccines (Basel); 2020 Dec; 8(4):. PubMed ID: 33287413
[TBL] [Abstract][Full Text] [Related]
17. TALEN-mediated genome-editing approaches in the liverwort
Kopischke S; Schüßler E; Althoff F; Zachgo S
Plant Methods; 2017; 13():20. PubMed ID: 28360929
[TBL] [Abstract][Full Text] [Related]
18. Generation of Stable Knockout Mammalian Cells by TALEN-Mediated Locus-Specific Gene Editing.
Mahata B; Biswas K
Methods Mol Biol; 2017; 1498():107-120. PubMed ID: 27709571
[TBL] [Abstract][Full Text] [Related]
19. Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells.
MacLeod DT; Antony J; Martin AJ; Moser RJ; Hekele A; Wetzel KJ; Brown AE; Triggiano MA; Hux JA; Pham CD; Bartsevich VV; Turner CA; Lape J; Kirkland S; Beard CW; Smith J; Hirsch ML; Nicholson MG; Jantz D; McCreedy B
Mol Ther; 2017 Apr; 25(4):949-961. PubMed ID: 28237835
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the editing patterns and editing efficiencies of TALEN and CRISPR-Cas9 when targeting the human CCR5 gene.
Nerys-Junior A; Braga-Dias LP; Pezzuto P; Cotta-de-Almeida V; Tanuri A
Genet Mol Biol; 2018; 41(1):167-179. PubMed ID: 29583154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
